AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal
Sees Potential Beyond Vaccines
Executive Summary
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
You may also be interested in...
Moderna Makes Major mRNA Commitment To UK
The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.
Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1
A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.
Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.